Akeso doses first patient in Phase III cadonilimab perioperative trial for MSI-H/dMMR colon cancer

• Akeso dosed the first patient in a Phase III perioperative trial of cadonilimab for resectable MSI-H or dMMR colon cancer.
• The study tests cadonilimab alone in pre-surgery and post-surgery treatment, targeting a setting with no approved perioperative immunotherapy.
• Earlier Phase II results were presented at the 2024 ESMO Immuno-Oncology Congress, showing strong tumor clearance before surgery with manageable safety.
• The move extends cadonilimab beyond advanced disease into curative-intent use, widening its late-stage development footprint and potential commercial reach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610100041PR_NEWS_USPR_____CN69368) on October 10, 2026, and is solely responsible for the information contained therein.